IP Library › Granted Patent US 6,861,055
Granted Patent B2
US 6,861,055 · App. 09/878,574 · Granted Mar 1, 2005

Human GDP-mannose 4,6-dehydratase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,861,055
App. No.
09/878,574
Granted
Mar 1, 2005
Kind
B2
Abstract

The invention provides a novel GDP-mannose 4,6-dehydratase.

Claims (41)

1. A method for treating a subject having an inflammatory disorder, wherein the inflammatory disorder is characterized by excessive GDP-mannose 4,6 dehydratase (GM4,6D) activity or excessive GM4,6D nucleic acid expression, comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is a polyclonal antibody.

4. The method of claim 1 , wherein the antibody is capable of binding to a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

5. A method for treating a subject having an inflammatory disorder characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression and chosen frown arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke and infection, comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.

6. The method of claim 5 , wherein the antibody is a monoclonal antibody.

7. The method of claim 5 , wherein the antibody is a polyclonal antibody.

8. The method of claim 5 , wherein the inflammatory disorder is arthritis.

9. The method of claim 5 , wherein the inflammatory disorder is transplant rejection.

10. The method of claim 5 , wherein the inflammatory disorder is asthma.

11. The method of claim 5 , wherein the inflammatory disorder is stroke.

12. The method of claim 5 , wherein the inflammatory disorder is infection.

13. A method of treating a subject having an inflammatory disorder characterized by excessive GM4,6D polypeptide activity comprising administering to the subject a compound, wherein said compound modulates GM4,6D polypeptide activity when combined with a substrate and a GM4,6D polypeptide chosen from:

(1) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 1;

(2) a polypeptide of SEQ ID NO: 2;

(3) a polypeptide of SEQ ID NO: 3;

(4) and a fragment of the polypeptide of SEQ ID NO:2 or SEQ ID NO: 3, which has GM4,6D activity.

14. The method of claim 13 , wherein the compound is an antibody that binds the GM4,6D polypeptide.

15. The method of claim 13 , wherein the antibody is a monoclonal antibody.

16. The method of claim 13 , wherein the antibody is a polyclonal antibody.

17. The method of claim 1 , wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

18. The method of claim 1 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

19. The method of claim 1 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.

20. The method of claim 5 , wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

21. The method of claim 5 , wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:3.

22. The method of claim 5 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

23. The method of claim 5 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.

24. The method of claim 5 , wherein the inflammatory disorder is sepsis.

25. The method of claim 5 , wherein the inflammatory disorder is reperfusion injury.

26. The method of claim 14 , wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

27. The method of claim 14 , wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:3.

28. The method of claim 14 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

29. The method of claim 14 , wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.

30. The method of claim 13 , wherein the inflammatory disorder is chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke and infection.

31. The method of 30 , wherein the inflammatory disorder is arthritis.

32. The method of claim 30 , wherein the inflammatory disorder is transplant rejection.

33. The method of claim 30 , wherein the inflammatory disorder is asthma.

34. The method of claim 30 , wherein the inflammatory disorder is sepsis.

35. The method of claim 30 , wherein the inflammatory disorder is reperfusion injury.

36. The method of claim 30 , wherein the inflammatory disorder is stroke.

37. The method of claim 30 , wherein the inflammatory disorder is infection.